Rocket Pharmaceuticals (RCKT) EBITDA (2014 - 2026)

Rocket Pharmaceuticals has disclosed EBITDA across 13 years of filings, most recently posting -$48.5 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$48.5 million, up 24.66% year-over-year; the trailing twelve-month figure through Mar 2026 was -$215.9 million (up 20.11% YoY), and the FY2025 annual result was -$231.7 million, up 15.17% from the prior year.
• EBITDA came in at -$48.5 million for Q1 2026 at Rocket Pharmaceuticals, down from -$44.0 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$42.6 million in Q1 2022 to a low of -$73.7 million in Q2 2024.
• The 5-year median for EBITDA is -$63.3 million (2023), against an average of -$61.0 million.
• Across the five-year window, EBITDA sank 59.22% in 2022 and advanced 29.88% in 2025, its largest moves.
• Rocket Pharmaceuticals' EBITDA stood at -$69.1 million in 2022, then climbed by 8.4% to -$63.3 million in 2023, then gained by 0.92% to -$62.7 million in 2024, then rose by 29.88% to -$44.0 million in 2025, then decreased by 10.35% to -$48.5 million in 2026.
• The last three EBITDA figures came in at -$48.5 million (Q1 2026), -$44.0 million (Q4 2025), and -$52.2 million (Q3 2025), per Business Quant data.